InSite Vision, Inc.

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Sep. 3, 2015, 4:35 PM
    • InSite Vision (OTCQB:INSV) reports that it has received a second unsolicited proposal from a global pharmaceutical company to acquire all of its outstanding shares for $0.35 in cash, topping its previous bid of $0.25 per share.
    • InSite is currently a party to a merger agreement with QLT (NASDAQ:QLTI) that is an all-stock transaction with a collared range of $0.25 - 0.30 per share.
    • InSite's board intends to carefully review the cash bid.
    | Sep. 3, 2015, 4:35 PM
  • Aug. 21, 2015, 8:46 AM
    | Aug. 21, 2015, 8:46 AM
  • Aug. 12, 2015, 6:49 AM
    | Aug. 12, 2015, 6:49 AM
  • Aug. 10, 2015, 9:20 AM
    • InSite Vision (OTCQB:INSV) announces that it has received an unsolicited offer from an undisclosed pharmaceutical firm to acquire all the outstanding shares of InSite common stock at $0.25 per share, a 43% premium over Friday's close of $0.175.
    • InSight is currently a party in a merger agreement with QLT in which InSight shareholders would receive 0.048 QLT shares for each INSV share. Its board of directors will carefully review the new proposal and pursue the course of action that best aligns with the interests of its shareholders.
    • Shares are up 9% premarket on light volume.
    | Aug. 10, 2015, 9:20 AM
Company Description
InSite Vision is committed to advancing new and superior ophthalmologic products for unmet eye care needs. The Company's lead product is AzaSite*, which targets infections of the eye. AzaSite contains the drug azithromycin, a broad-spectrum antibiotic formulated with DuraSite, InSite Vision's... More